Masters of Longevity - The Pulse

Fight Aging!24 Jul 2026
AISORLA Upregulation as a Possible Means to Treat Tauopathies (Fight Aging!)

SORLA Upregulation as a Possible Means to Treat Tauopathies

Research-focused article previewing work on boosting a neuronal trafficking protein to slow tau-driven neurodegeneration, with experimental mouse-model evidence.

Key takeaways
  • Up-regulating the endosomal trafficking receptor SORLA reduced tau phosphorylation and seeding in a PS19 mouse model.
  • Increased SORLA expression lessened synapse loss, ventricular enlargement, and LTP impairment in aged tauopathy mice.
  • SORLA up-regulation also decreased glial hyperactivation, suggesting reduced neuroinflammation linked to tau toxicity.
MoL Editorial24 Jul 2026
Can Doctors Be Trained for the Longevity Era? (MoL Editorial)

Can Doctors Be Trained for the Longevity Era?

A new global survey suggests that healthy longevity medicine education can change how physicians think and talk about ageing. But the evidence also highlights how much work remains before a rapidly growing field becomes routine clinical care.

MoL Event Pick
MedTech World Asia | Hong Kong 2026 (Hong Kong, Hong Kong)

MedTech World Asia | Hong Kong 2026

26. AUG 2026 - 28. AUG 2026 - Hong Kong, Hong KongSummit

Hong Kong summit connecting MedTech and HealthTech leaders, startups, investors, hospital executives, regulators and innovators across APAC healthcare innovation.

PR Newswire24 Jul 2026
AILaminar Pharma Announces "Last Patient, Last Visit" in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients (PR Newswire)

Laminar Pharma Announces "Last Patient, Last Visit" in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients

A news release announcing completion of patient follow-up in a late-stage clinical trial of an oral membrane lipid therapy for newly diagnosed glioblastoma; read to learn what trial milestone was reached and what next steps and analyses the article previews.

Key takeaways
  • Phase 2b/3 trial reached last patient, last visit with 144 enrolled glioblastoma patients.
  • Topline overall survival results are expected in the second quarter of 2027 after data lock.
  • Safety remained consistent and the LAM561 plus standard of care regimen was well tolerated.
Frontiers - Health24 Jul 2026
AIRecombinant LH priming improves follicular efficiency and pregnancy outcomes in women with diminished ovarian reserve undergoing antagonist IVF stimulation (Fro

Recombinant LH priming improves follicular efficiency and pregnancy outcomes in women with diminished ovarian reserve undergoing antagonist IVF stimulation

Report on using recombinant luteinizing hormone priming with oral contraceptive scheduling to improve ovarian stimulation efficiency and pregnancy outcomes in low-reserve patients.

Key takeaways
  • LH priming reduced cycle suspension before oocyte retrieval from 10.1% to 1.1%.
  • Follicular output rate improved to 59.4% with LH priming versus 52.8% without.
  • Ongoing pregnancy per started cycle rose to 18.3% with LH priming versus 9.4% without.